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Members of the PI3K/Akt/mTor signaling cascade are among the most frequently altered proteins in cancer, yet the
therapeutic application of pharmacological inhibitors of this signaling network, either as monotherapy or in
combination therapy (CT) has so far not been particularly successful. In this review we will focus on the role of
PI3K/Akt/mTOR in two distinct tumors, Glioblastoma multiforme (GBM), an adult brain tumor which frequently
exhibits PTEN inactivation, and Neuroblastoma (NB), a childhood malignancy that affects the central nervous system
and does not harbor any classic alterations in PI3K/Akt signaling. We will argue that inhibitors of PI3K/Akt signaling
can be components for potentially promising new CTs in both tumor entities, but further understanding of the
signal cascade’s complexity is essential for successful implementation of these CTs. Importantly, failure to do this
might lead to severe adverse effects, such as treatment failure and enhanced therapy resistance.
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Modern cancer therapy aims at eradicating tumors by
predominately inducing apoptosis, a form of programmed
cell suicide, via DNA damage and is thus limited by emer-
ging resistance of cancerous cells and toxic side effects on
healthy tissue. In order to circumvent these limitations,
combination therapy (CT) that combines cytotoxic agents,
such as chemo- or radiotherapy at metronomic doses
with at least one molecular-targeted agent, i.e. a pharma-
cological inhibitor of signaling cascades, has been pro-
posed to break apoptosis resistance, while concurrently
lowering adverse side effects [1]. The PI3K/Akt/mTOR
survival signaling cascade is frequently considered a
promising target in modern CT, particularly as PTEN,
its negative regulator, is among the most frequent mutated
proteins in cancer [2]. Small molecule compounds that
inhibit members of the PI3K signaling network, either
pan-specific, on the level of individual protein classes or
even isoform-specific, are being developed and clinically
evaluated by several companies [3,4]. However, despite
promising preclinical data, clinical successes so far have* Correspondence: Klaus-Michael.Debatin@uniklinik-ulm.de
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unless otherwise stated.been limited. There is mounting evidence that the
discrepancy between preclinical and clinical data is due
to the intrinsic complexity of the PI3K/Akt/mTOR
signaling cascade, so that the reductionist view of PI3K
signaling as a mere linear 'survival pathway' seems no
longer appropriate:
1) Signaling cascades, such as the PI3K/Akt/mTOR
pathway, are often depicted as a linear cascade, their
activation akin to a row of dominoes falling, with
individual signaling arms running parallel (at the same
speed) with occasional feedback loops. However, the
reality is more in line with a Rube Goldberg Machine.
These pathways have evolved out of more primitive
cascades, often with different functions, have
recruited proteins and whole side arms and thus
created overlapping or even diametrically opposite
functions. A signaling cascade is not maintained in a
population – be it mammal, human or tumor – due
to its efficacy or elegance, but remains active in a
population if it is the best current option that a) does
what it needs to do and b) is available to said
population. This, in turn, means that there is no
simple linear relationship between degree of inhibition
and tumor cell death. In other words our data,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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indicate maximal PI3K inhibition does not equal
maximal sensitization for cell death [5,6].
2) Taking the evolutionary origins of cellular signaling
pathways into account, the notion of a survival
pathway that can be inhibited by taking out a central
component appears greatly simplistic. The notion of
distinct signaling cascades that overlap is a human
construct, probably not dissimilar to the Linnæan
classification system, useful most of the time, but
not reflecting the whole biological truth. For example,
there is mounting evidence that the PI3K/Akt/mTOR
pathway and the Ras/MEK/Erk signaling cascade
are – at least in some cellular systems – so entwined
that one could really view them as a single, even more
complex survival machinery (with a canopy of
additional functions) [7]. Therefore, blocking an
individual component is not comparable to
figuratively blowing up a railroad bridge and thus
stopping the cancer train, but more like blocking the
highway forcing cancer to take the byroads and local
diversions, slowing down progression, but with the
minor risk of the discovery of a novel shortcut.
Taking these two caveats into account our answer to
the question Is the PI3K signaling network still a promising
target for cancer therapy? is Yes, but it is not the magic
bullet hoped for.
Review
Glioblastoma and PI3K signaling
Glioblastoma multiforme (GBM) is the most common
primary tumor of the central nervous system in adults
[8] and with a mean patient survival of 15 months after
treatment initiation, it is considered to be among the
most lethal cancers [9]. The current standard of care
consists of tumor resection followed by radiotherapy
and a course of Temozolamide [10]. As PTEN expres-
sion is reduced by mutation or loss of heterozygocity in
5-40% and 60-80%, respectively [11], and PI3K/Akt/
mTOR signaling is elevated in ~88% of all glioblastoma
[12,13], the addition of pharmacological inhibitors to
current treatment schedules should lead to clear thera-
peutic benefits. Indeed several clinical trials have been
initiated to study this hypothesis [14], but most have led
to no significant therapeutic improvement, or – in the
case of bevacizumab – have yielded rather controversial
results [15]. So far, aside from two mTOR (complex 1)
inhibitors, Everolimus and Temsirolimus, no drug target-
ing the PI3K/Akt/mTOR pathway specifically has been
approved [14].
The first interesting point of note is that inhibition
of PI3K signaling does not lead to apoptosis induction,
although this has been reported for other tumor entities,such as Hodgkin lymphoma [16]. Furthermore, as soon as
patients are treated with Temozolamide the presence or
absence of PTEN within the tumor is irrelevant for any fu-
ture prognostic development [11], the same phenomenon
holds true for activated Akt [17]. In contrast, activity of
the mTOR arm of the signaling cascade is associated with
poor patient survival [17]. However, due to its complex
role in several cellular processes [18], in particular autoph-
agy, which may lead to increased or reduced cell survival
[19] and the upregulation of ERK signaling upon its in-
hibition [20], mTOR is generally considered a difficult
target in glioblastoma [21]. Furthermore, frequently
the promising in vitro data regarding mTOR inhibition
in Glioblastoma cells does not translate well into an
in vivo setting (for example [22]).
Our own initial data analyzing a panel of Glioblastoma
cell lines responding to CT combining inhibition of
PI3K signaling and various chemotherapeutic agents,
as well as death receptor ligands also yielded several
interesting points [23,24]: PI3K signaling contributes
to therapy resistance in GBM cell lines, independently
of PTEN status. However, this contribution seems
stronger when cells are additionally stressed, i.e. serum-
starved. Importantly, the observed effects often do not
appear particularly strong, making it hard to argue that
the PI3K/Akt/mTOR signaling cascade is the main
mediator of apoptosis resistance in GBM. The above
described clinical data seem to support these inferences,
which leads to the question: Why then is this pathway
so frequently mutated in GBM? We suggest three possible
reasons that might explain this apparent contradiction.
They are by no means mutually exclusive and are all
supported by the literature.
1) Activation of PI3K signaling functions as a driver
mutation for the cell of origin to re-acquire stem
cell characteristics/re-enter the cell cycle. While
the cell of origin is still strongly debated in GBM
[25], primary GBM, the more common form
making up 91-95% of all GBM [26], apparently
arise de novo within 3–6 months [26], suggesting
rapid proliferation in a tissue which generally exhibits
rather little cell division. This is of particular
interest if GBM does not arise from neural stem
cells or oligodendrocyte precursor cells [27], but
de-differentiated astrocytes [25], and would fit with
the observation that inhibition of PI3K signaling
GBM primary affects proliferation [28,29]. The
most compelling data for this hypothesis comes
from work in T cell acute lymphoblastic leukemia
where it could be shown that activated AKT signaling
enhanced the frequency of leukemia propagating cells,
which can be considered in this context as tumor
stem cells [30].
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characteristic for GBM, both in terms of motility
and survival under stress. An association with FAK
and Src has long been established for PI3K
(for example [31,32], thus linking it to signaling
complexes associated with adhesion, motility and
invasion [33]. Recent data seem to link Akt/mTOR
activity directly to GBM motility [34], which is of
particular interest as this would suggest a
connection between two almost ubiquitous features
of GBM, high activity of the PI3K signaling cascade
and tumor dissemination throughout the whole
brain [35,36].
3) The central role of PI3K/Akt/mTOR in GBM
biology has led us grossly to underestimate its
importance. As shown above PI3K has clearly other
roles besides survival in GBM, it contributes to
motility (point 2) and proliferation (point 1). This
would suggest that PI3K signaling has several
contradictory functions in GBM. For example, high
proliferation is usually associated with therapy
sensitivity [37], yet inhibition of PI3K signaling can
lead to both reduced proliferation [28,29] and
chemosensitization [23,24]. This notion does not
negate the use of pharmacological PI3K inhibitors in
CT, but rather indicates the design of CT needs to
be carefully considered.
Interestingly, the importance of the last point is em-
phasized by our work mainly conducted on a different
tumor system, Neuroblastoma (NB).
Neuroblastoma and PI3K signaling
NB is a common childhood neoplasia of the sympathetic
nervous system that is generally characterized as a highly
heterogeneous disease and categorized into four stages,
of which stage 1 and 2 have a good prognosis. However,
prolonged survival for patients with stage 3 and 4 is only
18-30% [38,39]. Unfortunately 45% of patients exhibit
high-risk tumors, most of which have already metastasized
at clinical presentation [40]. Interestingly, NB lacks the
mutations in PI3K signaling that characterize GBM and
other tumors and a role for PI3K in NB was first consid-
ered due to its close association with the mycN oncogene
[41] and its prominent role downstream of growth
factor-initiated signaling, such as IGF-1 and IGF-2 [42].
More recently, the role of the ALK receptor tyrosine
kinase has also been highlighted in NB. It is expressed
in over 90% of all NB [43] and found to be activated by
mutation in 6.9% [44]. One of the downstream survival
cascades activated by ALK is PI3K/Akt signaling [42].
Our own group previously showed that in NB phosphory-
lated Akt correlates with poor patients' prognosis [45],
while others subsequently demonstrated a link betweenPI3K signaling and growth/survival [46], as well as resist-
ance to chemotherapy [47].
However, more recently following some previous hints
concerning the underlying molecular mechanisms of
how PI3K signaling affects chemosensitivity in NB [48],
we were surprised to discover that the relationship
between PI3K signaling and chemosensitivity is not as
simple as we had assumed [5]. Maximal, prolonged
inhibition of PI3K signaling did not sensitize NB cell
lines for Doxorubicin-induced apoptosis. Indeed under
certain conditions even a desensitization could be ob-
served [5]. This might be due to a combination of the
potent anti-proliferative effect of PI3K/mTOR inhib-
ition in NB cells and the induction of autophagy [5],
although it should be pointed out that autophagy in
NB is controversially discussed, as in most tumor
entities, and can be a survival mechanism as well as a
cell death enhancer (for example [49,50]). While con-
current treatment with a chemotherapeutic agent and a
pharmacological inhibitor of PI3K signaling led mostly
to good apoptosis sensitization, it was the application of
the inhibitor several hours after the cell death inducer
that yielded the best results [5]. We traced this particular
effect to the mitochondria, i.e. the modulation of VDAC1
via Akt-mediated phosphorylation of GSK3β [5].
Importantly, as we found a similar temporal effect in
GBM cells, this led us to propose a model which de-
emphasizes the maximal inhibition of a target signaling
cascade (clinically: high plasma levels of a pharmaco-
logical inhibitor prior to chemotherapy) and concen-
trates on the temporal relationship of the two treatment
components, i.e. sequential dosing [5].
Pathway complexity: when and where?
Next, one needs to consider at which point in the signaling
cascade to intervene. While in the past a preferred target
seems to have been the dual inhibition of PI3K and mTOR
[3], thus taking out a major section of the signaling cascade
and ablating a potent feedback mechanism, currently there
seems to be a shift towards inhibitors of Akt [4]. However,
as emerging data suggest that Akt is not the central medi-
ator of PI3K, i.e. inhibition of Akt signaling is not identical
with inhibition of PI3K signaling [7], this target appears
less promising. In particular, inhibition of PI3K can also
block Ras/ERK signaling, while inhibition of Akt does not
and is thus less efficient [7].
To consider the optimal target of PI3K signaling
inhibition one has first to understand its role. Our data
[5] provides strong evidence for the third proposition
we put forward, indicating that we have previously
underestimated the complexity of PI3K signaling. Im-
portantly, this does not necessarily invalidate the other
two options. In a model we and others [5,6] suggest the
PI3K signaling cascade regulates two or three aspects of
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one hand proliferation and metabolism (the inhibition
of which can have adverse effects on chemo- and radio-
therapy [5,6], e.g. hyperactivation of Akt in this context
has even been proposed as a therapeutic option [51]),
on the other hand survival, particularly under stress.
Importantly, these competing effects of the PI3K signaling
network are mediated by different arms of the cascade at
different speeds, giving us two therapeutic strategies to
employ.
The approach we – and also, apparently, the Djuzenova
group – favor is the use of existing, clinically evaluated
pharmacological inhibitors of the PI3K signaling, while
optimizing the treatment schedule so as concurrently to
maximize the effect on survival and minimize the effect
on proliferation/metabolism [5,6]. Alternatively, a strategy
could be envisioned whereby not the main components
of the PI3K signaling cascade are targeted, but either
proteins that are further upstream, apical to several, po-
tentially compensatory networks, such as the MEK/Erk
signaling cascade [7], or further downstream at the level
of molecules that clearly only contribute to survival in
the context of CT, such as the Bcl-2-family [48].
The epidermal growth factor receptor (HER1/EGFR) is
one of the most frequently dysregulated oncogenes in
glioblastoma [52]. About half of GBM show amplification
of HER1/EGFR and of these about another half coexpress
EGFRvIII, the continuously activated mutant form of the
receptor [53]. In preclinical studies, treatment with HER1/
EGFR-targeted agents such as monoclonal antibodies
or small-molecule inhibitors, e.g. erlotinib (Tarceva;
Genentech Inc.) were shown to exert promising antineo-
plastic activity in various in vitro and in vivo models in the
setting of GBM [52,54,55]. These effects were at least in
part related to inhibition of PI3K/Akt and MAPK signaling.
However, when taken into the clinics HER1/EGFR inhibi-
tors did not hold up to the expectations derived from the
promising preclinical results [56-58]. Treatment with
erlotinib did not result in a survival benefit either as
a single agent therapy [58] or when combined with
temozolomide and radiation [57]. Thus, at this point,
upstream targeting of PI3K by inhibition of HER1/EGFR
did not fulfill hopes in improving the fate of patients with
GBM. One potential explanation for this finding is that
PI3K signaling may be uncoupled from upstream control
by inactivation of PTEN, the previously mentioned negative
regulator of PI3K signaling (Figure 1).
In vitro, Fan and coworkers showed that PTEN mutant
U87 cells were much less responsive to a treatment with
erlotinib alone when compared to PTEN wild type
LN229 cells [59]. Others reported similar findings [60].
In both studies, additional inhibition of either mTOR by
rapamycin or PI3K/mTOR by PI-103 resulted in a sensi-
tizing effect on PTEN mutated glioma cells towardsHER1/EGFR inhibition by erlotinib. However, in a clinical
setting, the results of a phase I/II pilot study of 22 patients
with recurrent GBM treated with the mTOR inhibitor
everolimus and the HER1/EGFR inhibitor gefitinib were
rather mixed [61].
While identification of potential upstream targets seems
less advanced in NB than in GBM, ALK presents itself as
a promising candidate, but – although pharmacological
inhibitors such as crizotinib are available – preclinical and
early clinical trials do not appear promising. It seems that
an almost complete inhibition of ALK is needed for a clin-
ical response, while resistance to the inhibitor can develop
relative rapidly, as is also the case with HER1/EGFR [62].
Similar to the combination of an HER1/EGFR inhibitor
with blocking mTOR signaling in GBM, the combination
of mTOR and ALK inhibition in NB is also of therapeutic
benefit [63].
These findings in GBM and NB clearly indicate that
CT with several inhibitors (of a single signaling network)
of which some are upstream of PI3K can lead to enhanced
therapeutic responses.
To avoid the inhibition of additional side arms of
the signaling cascades or activation of compensatory
mechanisms rather specific individual targets should
be considered, but therefore the precise executor molecule
for survival needs to be identified. We have identified
DNA-PK, i.e. the DNA repair axis of PI3K signaling, as
the crucial inhibitor of survival when GBM cells are
challenged with Doxorubicin [24]. However when NB
are treated with the same drug GSK-3 and VDAC, i.e.
the mitochondrial arm of PI3K signaling, are crucial [5]
(Figure 2). Further experiments are needed to find out
whether these differences are indeed due to the specific
tumor entity, the interplay between treatment and genetic
make-up, or different role of the PI3K signaling cascade in
different cells. As long as these questions are unanswered
downstream molecules, despite the presumed lower side
effects, remain undesirable, particularly, as a single end-
point target increases the risk of mutational escape, as
seen, for example, with Gleevec [64].
Importantly, our data suggest that one does not have
to pick a single or – in case of the dual PI3K/mTOR
inhibitors - a double target, but that multiple, carefully
timed inhibitions of what is generally considered a sin-
gle signaling cascade can cooperate and thus produce a
greater sensitizing effect [5]. Therefore it is feasible,
from a purely biological perspective, to imagine a
therapeutic approach that uses a stepwise inhibition of
PI3K signaling both to extent the therapeutic window
and enhance cell death (Figure 3). How such an ap-
proach could be translated into a clinical setting and
whether cumulative inhibition of signaling might lead to
unforeseen side effects are the key remaining challenges
that need to be overcome.
Figure 1 The PI3K/Akt/mTOR signaling cascade. Simplified schemata of the PI3K/Akt/mTOR signaling cascade. While indisputable involved at
several levels, directly as well as indirectly with cell survival, other important functions of this signaling network are also highlighted here. Key
molecules which have been implicated in cancer or have been selected as potential therapeutic targets are: 1. Receptor tyrosine kinases, such as
EGFR, IGFR and ALK, often overexpressed or activated by mutations in many different cancers, including glioblastoma and neuroblastoma. These
transmembrane proteins are apical of several interconnected signaling cascades. 2. PI3K, phosphatidylinositol 3'-OH kinase, a lipid kinase,
predominately consisting of a p110 catalytic and a p85 regulatory subunit, of which the former has been found to be mutationally activated in
certain cancers. 3. PTEN, phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P3] phosphatase and tensin homologue, is a phosphatase that
counters PI3K-mediated phosphorylation and as such functions as a negative regulator of the PI3K/Akt/mTOR signaling cascade. It is among the
most frequently inactivated, either by mutation or promoter methylation, proteins in cancer. 4. The serine/threonine kinase Akt, v-akt murine
thymoma viral oncogene homologue (Protein Kinase B), is often considered the central downstream mediator of PI3K signaling, as it phosphorylates a
diverse array of targets that are involved in all key functions of this pathway. 5. mTOR, mammalian target of Rapamycin, depending on its complex
partners, can either be up- or downstream of Akt. It is frequently found to be associated with the process of autophagy, which depending on the
context, can be either a survival strategy or a form of cell death. (modified from [33]).
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Crosstalk between proneoplastic signaling pathways (or,
depending on the perspective: underestimated complex-
ity of a single signaling network) is abundant in both
GBM [65] and NB [66,67] and is regarded as one of the
major culprits responsible for the failure of targeted
therapies. In addition, it has also become apparent in the
last decade or so that the number of mutations found in
cancers is considerably higher than estimated: While
only a handful are needed to initiate tumor progression,
an excess of 10,000 mutations is found in many malig-
nancies [68]. Although many of these will not contribute
to the malignant phenotype and might even be present
in benign neoplasms [68], other mutations will affect thecancer cells' behavior. With such a complexity, it is not
surprising that blocking a single signaling cascade, either
alone or as part of a CT approach, has not been success-
ful. Indeed, viewed in this context it is actually surprising
what a potent tool inhibition of PI3K signaling is!
As a consequence, multi-targeting has been developed
as a therapeutic strategy to overcome this potential mech-
anism of resistance by combining two or more agents tar-
geting different oncogenic signaling pathways, or targeting
a single oncogenic signaling pathway differently in the
sense of a combined forces alliance driving the cancer cells
to undergo cell death [5,69-72]. Frequently, the inhibition
of PI3K signaling is considered a promising contributor
to CTs.
Figure 2 (See legend on next page.)
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Figure 2 Potential tumor-specific differences in therapeutic end points. Although inhibition of PI3K/Akt/mTOR signaling is a feasible
approach in both glioblastoma and neuroblastoma, the molecular background of those two malignancies is very different. While glioblastoma
exhibits amplification of HER1/EGFR with coexpression of the activated EGFRvIII variant [53], their main feature with regards to the PI3K signaling
network is the frequent inactivation of PTEN [11]. In contrast, neuroblastoma does not exhibit any frequent mutation within the PI3K/Akt/mTOR
signaling cascade, but often displays overexpression of several receptor tyrosine kinases [42,43]. Interestingly, our own data suggest that the
downstream effectors that need to be inhibited to chemosensitize these tumors to chemotherapy are different. Glioblastoma is sensitized for
doxorubicin-induced apoptosis via blocking DNA-PK activation, i.e. DNA repair [24], while in neuroblastoma this seems to be mediated at the level
of mitochondria via VDAC1 [5]. It remains to be seen whether this is an isolated phenomenon, due to low numbers of cell lines investigated, or
whether different arms of the PI3K network have a different weighting dependent on the malignancy.
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to a cytostatic effect, not only in the aforementioned
Hodgkin lymphoma [16], but also in both GBM [28,29]
and NB [41,73]. We have argued elsewhere [33] that an
approach that aims to chronify a malignancy rather than
an attempt to cure a patient can be the preferable strategy,Figure 3 Possible future treatment schedule. A possible complex combi
that all target individual components of the PI3K signaling cascade. 1. Tak
metastasis, extending the therapeutic window. Continue blocking this arm
treatment. Importantly do not affect cell cycle progression, thus making c
chemo- or radiotherapy. 4. Block the survival pathways mediated by PI3K
Figure 2, details of key mediators are know, e.g. DNA-PK in glioblastoma (4.1),
most promising target. 5. Finally, block growth factor receptors to maximize c
escaped treatment-induced apoptosis. Point 5 might appear superfluous, as 3
also target cells that have activated additional signaling cascades or have (epwhile others have also pointed out that prolonged cytosta-
sis can ultimately lead to a cytotoxic event, if the tumor
cells fail to escape this proliferation block [74]. For CT an
antiproliferative effect of the sensitizer is often considered
a hindrance, as it has often been suggested that rapid pro-
liferation coincides with increased treatment sensitivitynation therapy that consists of a cell death inducer and several sensitizer
e out the cancer cells' ability to move, thus preventing invasion and
throughout therapy. 2. Block the DNA repair mechanisms prior to
ancer cells amenable to most standard treatments. 3. Administer
signaling in the cancer cells stressed by treatment. If, as outlined in
or VDAC1 in neuroblastoma (4.2), target these, otherwise Akt seems the
ell cycle arrest, thus preventing a cancer repopulation by the cells that
and 4 should already block proliferation, however, this inhibition should
i)genetically escaped sensitivity to treatment.
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addition, there are several inducers of cell death which are
of therapeutic interest that exert their effects in a
proliferation-independent manner, such as death receptor
triggering [76,77], or treatment with amiloride derivatives
[78]. Most crucial, as outlined above, there is an emerging
line of argument that the carefully timed application of
sensitizer and inducer in CT can drastically affect the
outcome [5,6], suggesting that a carefully timed sequen-
tial application of inhibitor and sensitizer, together with
carefully selected targets for inhibition, quite possibly
several targets may lie within the same cascade, can
greatly enhance the anti-tumorigenic effect of CT. In
such a setting, pharmacological inhibition of PI3K/Akt/
mTOR may prove to be an invariable tool in our thera-
peutic arsenal.
While this review focuses on glioblastoma and neuro-
blastoma, the inhibition of PI3K-mediated signaling is cur-
rently also being clinically evaluated in several additional
tumor entities, such as lymphocytic leukemias, colorectal
cancer, head and neck cancer, several forms of lymphoma,
non-small cell lung cancer and renal cancer [79]. Indeed,
it is well-worth remembering that PTEN, the negative
regulator of this signaling cascade has often been cited as
the second most frequently mutated gene in cancer
and even as 'a new guardian of the genome' [80]. Since
neuroblastoma and glioblastoma are, with respect to
PI3K/Akt/mTOR signaling, two very different entities,
there is no a priori reason to assume that other tumors
will not be subject to the principles discussed here. For
example, sequential dosing, has already been demonstrated
to also be important in other malignancies, such as breast
cancer [81]. However, further research will be needed to
fully clarify this point.
With the current rapid advancement of sequencing
techniques [82,83], profiling [84,85] and molecular hist-
ology [8], our understanding of which targets in which
signaling cascade might represent promising targets will
become much clearer within the next few years. How-
ever, other challenges remain, such as how successfully
to translate the preclinical data into a clinical setting.
For example, our own cell culture work suggested that
in a complex CT approach to treat childhood GBM the
inhibition of PI3K was preferable to targeting mTOR,
however, applying these two combinations to an ortho-
topic xenotransplant mouse model indicated that the
CT that blocked PI3K had no beneficial effect on
mouse survival, while the therapy that targeted mTOR
significantly prolonged survival [72]. Importantly, on
analysing the tumours, we found indications that
suggested treatment failure of the first combination was
due to an additional effect on tumour vasculature that
prevented the chemotherapeutic agent from reaching the
malignancy [72]. This effect would have been undetectablein both cell culture and under local instead of systemic
treatment of the mice. In addition, while a cell culture
model and – to a certain extent – a preclinical animal
model enable the precisely sequential-timed application of
clearly defined concentrations allowing us fully to under-
stand which amount of a substance reaches the target
within what time frame, this luxury is not given in the
clinic. A systemic application of treatment is here the
norm and thus the precise understanding and control of
the complex pharmacokinetics will be essential.
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